Affordable Access

Access to the full text

Circulating extracellular vesicles expressing PD1 and PD-L1 predict response and mediate resistance to checkpoint inhibitors immunotherapy in metastatic melanoma

Authors
  • Serratì, Simona1
  • Guida, Michele1
  • Di Fonte, Roberta1
  • De Summa, Simona1
  • Strippoli, Sabino1
  • Iacobazzi, Rosa Maria1
  • Quarta, Alessandra2
  • De Risi, Ivana1
  • Guida, Gabriella3
  • Paradiso, Angelo4
  • Porcelli, Letizia1
  • Azzariti, Amalia1, 1
  • 1 IRCCS Istituto Tumori Giovanni Paolo II, V.le O. Flacco, 65, Bari, 70124, Italy , Bari (Italy)
  • 2 CNR NANOTEC-Istituto di Nanotecnologia, National Research Council (CNR), via Monteroni, Lecce, 73100, Italy , Lecce (Italy)
  • 3 University of Bari, Piazza G. Cesare, 11, Bari, 70124, Italy , Bari (Italy)
  • 4 Scientific Directorate, IRCCS Istituto Tumori Giovanni Paolo II, V.le O. Flacco, 65, Bari, 70124, Italy , Bari (Italy)
Type
Published Article
Journal
Molecular Cancer
Publisher
Springer (Biomed Central Ltd.)
Publication Date
Jan 18, 2022
Volume
21
Issue
1
Identifiers
DOI: 10.1186/s12943-021-01490-9
Source
Springer Nature
Keywords
Disciplines
  • Liquid Biopsy at the Frontier of Early Detection, Prognosis and Cancer Treatments
License
Green

Abstract

BackgroundThe immunotherapy with immune checkpoints inhibitors (ICI) has changed the life expectancy in metastatic melanoma (MM) patients. Nevertheless, several patients do not respond hence, the identification and validation of novel biomarkers of response to ICI is of crucial importance. Circulating extracellular vesicles (EVs) such as PD-L1+ EV mediate resistance to anti-PD1, instead the role of PD1+ EV is not fully understood.MethodsWe isolated the circulating EVs from the plasma of an observational cohort study of 71 metastatic melanoma patients and correlated the amount of PD-L1+ EVs and PD1+ EVs with the response to ICI. The analysis was performed according to the origin of EVs from the tumor and the immune cells. Subsequently, we analysed the data in a validation cohort of 22 MM patients to assess the reliability of identified EV-based biomarkers. Additionally we assessed the involvement of PD1+ EVs in the seizure of nivolumab and in the perturbation of immune cells-mediated killing of melanoma spheroids.ResultsThe level of PD-L1+ EVs released from melanoma and CD8+ T cells and that of PD1+ EVs irrespective of the cellular origin were higher in non-responders. The Kaplan-Meier curves indicated that higher levels of PD1+ EVs were significantly correlated with poorer progression-free survival (PFS) and overall survival (OS). Significant correlations were found for PD-L1+ EVs only when released from melanoma and T cells. The multivariate analysis showed that high level of PD1+ EVs, from T cells and B cells, and high level of PD-L1+ EVs from melanoma cells, are independent biomarkers of response. The reliability of PD-L1+ EVs from melanoma and PD1+ EVs from T cells in predicting PFS was confirmed in the validation cohort through the univariate Cox-hazard regression analysis. Moreover we discovered that the circulating EVs captured nivolumab and reduced the T cells trafficking and tumor spheroids killing.ConclusionOur study identified circulating PD1+ EVs as driver of resistance to anti-PD1, and highlighted that the analysis of single EV population by liquid biopsy is a promising tool to stratify MM patients for immunotherapy.

Report this publication

Statistics

Seen <100 times